MINNEAPOLIS--(BUSINESS WIRE)--Announcing a significant step toward the surgical treatment of lone atrial fibrillation (AF), Medtronic, Inc. (NYSE:MDT), today announced FDA approval to initiate the Feasibility of the Lone Atrial Fibrillation Clinical Trial (FACT). The trial initiation coincides with the launch of Medtronic’s Cardioblate® Navigator™ Tissue Dissector.
